Docs
All documentation Fundamental API Live (Delayed) API EOD Historical API Intraday API Real-Time (websockets) API Google Sheets add-on Excel add-on
Community
Academy 134 articles Forum Github 13 repos
Marketplace
Spreadsheets
Google Sheets add-on Excel add-on Wordpress plugin
Pricing
Overview Fundamentals API Earnings EOD API Sample Code Pricing
Register now
Free trial

No credit cards required

Get free API key
  1. Supported exchanges /
  2. PINK /
  3. HLOSF.PINK

Healios K.K (HLOSF PINK) stock market data APIs

$1.21 0(0%) as of July 25, 2024
Price chart is built with Anychart

Healios K.K. engages in the research and development, manufacture, and sale of cell therapy and regenerative medicine products in Japan, Europe, and the United States. The company offers HLCM051 for treatment of ischemic stroke and acute respiratory distress syndrome; HLCN061 for treating solid tumors; HLCR011 for the treatment of retinal pigment epithelium tear and age-related macular degeneration; and HLCL041 for liver disease. The company was formerly known as Retina Institute Japan, K.K. and changed its name to Healios K.K. in September 2013. Healios K.K. was incorporated in 2011 and is headquartered in Tokyo, Japan.

Healios K.K Financial Data Overview

1.21
1.21
-
1.21
1.21
0.9258-14.55
109 M
90 130 K
124 M
-0.1956
0.908
Our easy-to-use no-coding solutions help you get the data effortlessly:
Excel Financial Add-In Google Sheets Financial Add-In Python
APIs SDK Windows Downloader

No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.

General: {
Code: 'HLOSF',
Type: 'Common Stock',
Name: 'Healios K.K',
Exchange: 'PINK',
CurrencyCode: 'USD',
CurrencyName: 'US Dollar',
CurrencySymbol: '$',
CountryName: 'USA',
CountryISO: 'US',
OpenFigi: 'BBG00TTG8BG9',
ISIN: NULL,
CUSIP: NULL,
CIK: NULL,
EmployerIdNumber: NULL,
FiscalYearEnd: 'December',
IPODate: NULL,
InternationalDomestic: NULL,
Sector: 'Healthcare',
Industry: 'Biotechnology',
HomeCategory: NULL,
IsDelisted: false,
}

Healios K.K Fundamental Data is available in our Financial Data APIs

  • Net Revenue 124 M
  • EBITDA -3 385 999 872
  • Earnings Per Share -0.47
  • Income Statements
  • Balance Sheets
  • Cash flows
Fundamental data package from $59.99 See full price
Get sample
of Fundamental API Data

Get Healios K.K Earnings via APIs

  • Latest Release 2024-05-13
  • EPS/Forecast NaN

Get Healios K.K End-of-day Data via APIs

  • End of Day, Intraday and Live APIs
  • Splits
  • Dividends

Get Healios K.K latest news via APIs

Athersys and Healios K.K. Announce Advancement of Their MultiStem Commercial Partnership

Improvements to Collaboration Enhance Preparations for Commercial Activity in Japan CLEVELAND & TOKYO, August 05, 2021--(BUSINESS WIRE)--Athersys, Inc. (NASDAQ: ATHX) and HEALIOS K.K. (Healios) (TSE ...
  • ATHERSYS
  • COMMERCIAL REQUIREMENTS
  • HEALIOS
  • HEALIOS K.K
  • JAPAN
  • MANUFACTURING
  • MULTISTEM
  • REGULATORY APPROVAL

Healios Successfully Establishes Proprietary Universal Donor Cell Research Line

TOKYO, June 5, 2020 /PRNewswire/ -- Healios K.K. (hereinafter "the Company"; TSE: 4593), Japan's leading clinical-stage biotechnology company, has been creating Universal Donor Cells (UDCs), which are...
  • COMPANY
  • GENE EXPRESSION
  • HEALIOS K.K
  • IMMUNE CELLS
  • IMMUNE REJECTION
  • IMMUNE RESPONSE
  • IPS CELLS
  • JAPAN
  • REGENERATIVE MEDICINE
  • THE COMPANY
  • TRANSPLANTATION
  • UDC
  • UNIVERSAL DONOR CELLS
Do you have any questions?
support@eodhistoricaldata.com